Result of AGM
("RenalytixAI" or the "Company")
Result of AGM
The results of the AGM are detailed below:
|
Votes in Favour (% of votes cast) |
Votes against (% of votes cast)
|
Votes withheld |
Resolution 1
|
42,245,505 (91.38%)
|
3,986,275 (8.62%) |
2,569 |
Resolution 2
|
41,548,352 (89.87%)
|
4,685,392 (10.13%) |
605 |
Resolution 3 |
46,228,154 (99.99%)
|
1,526 (0.01%) |
4,669 |
Resolution 4
|
46,190,220 (99.91%) |
43,624 (0.09%) |
505
|
Resolution 5
|
46,071,032 (99.66%) |
157,813 (0.34%) |
5,504
|
Resolution 6
|
46,095,710 (99.73%)
|
127,083 (0.27%) |
11,556 |
Resolution 7
|
45,551,130 (99.88%)
|
54,530 (0.12%) |
628,689 |
Enquiries:
|
||
|
Via Walbrook PR |
|
|
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|
|
|
|
|
|
|
|
Tel: 020 7597 4000 |
|
|
|
|
|
|
|
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
|
Mob: 07980 541 893 / 07584 391 303 |
|
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The
* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the